Risk Factors for Relapse of Human Brucellosis

Background & Propose: Brucellosis is serious disease around the world, especially in underdeveloped countries. Relapse is major problem in therapy of brucellosis. This study aimed to evaluate risk factors of relapse after treatment in patients. Methods: It is a descriptive-analytic study from 1990 to 2014, in Ayatolla Rohani hospital in Babol, Iran. We studied 980 patients with brucellosis. The studied community included patients infected with brucellosis and the required information was gathered based on their hospital files. The base for recognizing Malta fever were clinical symptoms and Para-clinical sign congruent with infection like as, titer SAT>1:320 and 2-ME>1:160. Patients with relapse and patients without relapse were placed separately in two groups. The data were statistically compared with Spss 16, by Chi-square and Cox–regression tests. Results: Based on this study, treatment regimen is a preventive factor (P=0.000). Moreover, Based on some statistical methods, regimens no. 3 and 4 were introduce preventive factors (P=0.001) and (P=0.004). It should also be noted that findings the same statistical model, factors like gender, age, residence, professional contacts, complications and delay in treatment were also analyzed but none of them are considered as preventive factors. Conclusion: Based our finding, we suggest aminoglycosides (gentamicin or streptomycin with doxycycline) are associated with lower rate of relapse in brucellosis.

[1]  U. Magnusson,et al.  A Study of Knowledge, Attitudes and Practices Relating to Brucellosis among Small-Scale Dairy Farmers in an Urban and Peri-Urban Area of Tajikistan , 2015, PloS one.

[2]  Peng Jia,et al.  Human brucellosis occurrences in inner mongolia, China: a spatio-temporal distribution and ecological niche modeling approach , 2015, BMC Infectious Diseases.

[3]  R. L. Santos,et al.  Pathogenesis and pathobiology of brucellosis in livestock. , 2013, Revue scientifique et technique.

[4]  J. Ramazanpour,et al.  Epidemiological features of human brucellosis in central Iran, 2006-2011. , 2012, Public health.

[5]  E. Schelling,et al.  Global Burden of Human Brucellosis: A Systematic Review of Disease Frequency , 2012, PLoS neglected tropical diseases.

[6]  M. H. Hasanjani Roushan,et al.  Outcomes of treatment in 50 cases with spinal brucellosis in Babol, Northern Iran. , 2012, Journal of infection in developing countries.

[7]  H. Mahjub,et al.  Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[8]  J. Solera,et al.  Systematic Review and Meta-Analysis of Randomized Clinical Trials in the Treatment of Human Brucellosis , 2012, PloS one.

[9]  J. Solera Update on brucellosis: therapeutic challenges. , 2010, International journal of antimicrobial agents.

[10]  K. Ravikumar,et al.  Brucellosis: Review on the Recent Trends in Pathogenicity and Laboratory Diagnosis , 2010, Journal of laboratory physicians.

[11]  Ali Bijani,et al.  Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial. , 2010, The Journal of antimicrobial chemotherapy.

[12]  M. R. Roushan,et al.  Update on the treatment of adult cases of human brucellosis , 2008 .

[13]  E. J. Young,et al.  Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations , 2007, PLoS medicine.

[14]  M. Hajiahmadi,et al.  Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  A. Durak,et al.  Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647] , 2006, BMC infectious diseases.

[16]  M. Tevfik,et al.  Comparison of three different combination therapies in the treatment of human brucellosis , 2005, Tropical doctor.

[17]  G. Pappas,et al.  Effective treatments in the management of brucellosis , 2005, Expert opinion on pharmacotherapy.

[18]  J. Solera,et al.  A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  B. Mantur,et al.  Childhood brucellosis--a microbiological, epidemiological and clinical study. , 2004, Journal of tropical pediatrics.

[20]  E. J. Young,et al.  An overview of human brucellosis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  G. Araj,et al.  A multicenter therapeutic study of 1100 children with brucellosis. , 1989, The Pediatric infectious disease journal.